JP7150611B2 - 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法 - Google Patents

腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法 Download PDF

Info

Publication number
JP7150611B2
JP7150611B2 JP2018554648A JP2018554648A JP7150611B2 JP 7150611 B2 JP7150611 B2 JP 7150611B2 JP 2018554648 A JP2018554648 A JP 2018554648A JP 2018554648 A JP2018554648 A JP 2018554648A JP 7150611 B2 JP7150611 B2 JP 7150611B2
Authority
JP
Japan
Prior art keywords
acid sequence
nucleic acid
mva
seq
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018554648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500907A (ja
JP2019500907A5 (enExample
Inventor
ロビンソン，ハリエット
ドミ，アルバン
ヘラーステイン，マイケル
ギラッコー，ファーシャド
マッカーリー，ナサニエル・ポール
Original Assignee
ジオバックス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジオバックス・インコーポレイテッド filed Critical ジオバックス・インコーポレイテッド
Publication of JP2019500907A publication Critical patent/JP2019500907A/ja
Publication of JP2019500907A5 publication Critical patent/JP2019500907A5/ja
Priority to JP2022153352A priority Critical patent/JP2022185011A/ja
Application granted granted Critical
Publication of JP7150611B2 publication Critical patent/JP7150611B2/ja
Priority to JP2024019248A priority patent/JP2024056839A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001181—Alpha-feto protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018554648A 2016-01-08 2017-01-09 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法 Active JP7150611B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022153352A JP2022185011A (ja) 2016-01-08 2022-09-27 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法
JP2024019248A JP2024056839A (ja) 2016-01-08 2024-02-13 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276479P 2016-01-08 2016-01-08
US62/276,479 2016-01-08
US201662301885P 2016-03-01 2016-03-01
US62/301,885 2016-03-01
PCT/US2017/012704 WO2017120577A1 (en) 2016-01-08 2017-01-09 Compositions and methods for generating an immune response to a tumor associated antigen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022153352A Division JP2022185011A (ja) 2016-01-08 2022-09-27 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2019500907A JP2019500907A (ja) 2019-01-17
JP2019500907A5 JP2019500907A5 (enExample) 2020-01-30
JP7150611B2 true JP7150611B2 (ja) 2022-10-11

Family

ID=59274065

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018554648A Active JP7150611B2 (ja) 2016-01-08 2017-01-09 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法
JP2022153352A Ceased JP2022185011A (ja) 2016-01-08 2022-09-27 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法
JP2024019248A Ceased JP2024056839A (ja) 2016-01-08 2024-02-13 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022153352A Ceased JP2022185011A (ja) 2016-01-08 2022-09-27 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法
JP2024019248A Ceased JP2024056839A (ja) 2016-01-08 2024-02-13 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法

Country Status (9)

Country Link
US (3) US11278607B2 (enExample)
EP (1) EP3402802B1 (enExample)
JP (3) JP7150611B2 (enExample)
CN (2) CN109071592B (enExample)
AU (2) AU2017206102C1 (enExample)
CA (1) CA3011014A1 (enExample)
ES (1) ES2944314T3 (enExample)
PL (1) PL3402802T3 (enExample)
WO (1) WO2017120577A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3402802T3 (pl) 2016-01-08 2023-06-05 Geovax, Inc. Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym
WO2017136419A1 (en) 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
WO2019040846A1 (en) * 2017-08-25 2019-02-28 Geovax Inc. IMMUNO-ONCOLOGY COMPOSITIONS AND METHODS OF USE THEREOF
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
CN113056479A (zh) * 2018-10-05 2021-06-29 南特细胞公司 腺病毒疫苗媒介物中的cd40和cd40l结合物
CN114929268A (zh) * 2019-11-20 2022-08-19 巴法里安诺迪克有限公司 4-1bbl辅助的重组修饰的安卡拉痘苗病毒(mva)的医疗用途
EP4103231A4 (en) * 2020-02-14 2024-03-27 Geovax, Inc. VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
JP7584763B2 (ja) * 2020-06-04 2024-11-18 東亞合成株式会社 抗ウイルス性ペプチドおよびその利用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286074A1 (en) 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
CN101460627A (zh) 2006-06-20 2009-06-17 特朗斯吉有限公司 制备痘病毒的方法以及痘病毒组合物
JP2012507985A (ja) 2008-11-03 2012-04-05 リゴサイト ファーマシューティカルズ インコーポレイテッド 感染因子を含まないエンベロープウイルスベースｖｌｐを単離するための改良法
JP2013014588A (ja) 2005-01-24 2013-01-24 Gsf-Forschungszentrum Fuer Umwelt & Gesundheit Gmbh Ｍｖａの使用に基づくワクチン
JP2013507935A (ja) 2009-10-16 2013-03-07 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ 再構築された挿入部位を含有する組換え改変ワクシニアアンカラ（ｍｖａ）ワクシニアウイルス

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
AU570940B2 (en) 1982-11-30 1988-03-31 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for producing poxvirus recombinants for expression offoreign genes
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5445953A (en) 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
DE69133333T2 (de) 1991-08-26 2004-07-29 Baxter Healthcare S.A. Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken
ATE181108T1 (de) 1991-08-26 1999-06-15 Immuno Ag Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus
AU5679394A (en) 1992-11-25 1994-06-22 International Biotechnology Laboratories, Inc. Hepatitis b virus vaccines
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
WO1998008539A1 (en) 1996-08-26 1998-03-05 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
AUPP380598A0 (en) 1998-05-29 1998-06-25 Commonwealth Scientific And Industrial Research Organisation Genetically manipulated entomopoxvirus
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
CN1311871C (zh) 2000-03-02 2007-04-25 爱莫里大学 Dna表达载体及其应用方法
AU2002252199B2 (en) 2001-03-08 2008-01-03 Emory University MVA expressing modified HIV envelope, GAG, and POL genes
EP1279404A1 (en) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7211378B2 (en) * 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
WO2003078640A2 (en) 2002-03-15 2003-09-25 Baxter International Inc. Recombinant drug-sensitive vaccinia virus as smallpox vaccine
EP2253709B1 (en) 2002-05-16 2018-04-11 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
WO2004042001A2 (en) 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
AU2003251531A1 (en) * 2002-06-14 2003-12-31 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
DE10249390A1 (de) 2002-10-23 2004-05-13 Ruprecht-Karls-Universität Heidelberg Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
US20040109876A1 (en) 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV
DE60314541T2 (de) 2002-11-25 2008-02-28 Bavarian Nordic A/S Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
WO2005048957A2 (en) 2003-02-20 2005-06-02 Therion Biologics Corporation Novel insertion sites in pox vectors
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
US20060099225A1 (en) 2004-04-13 2006-05-11 Sina Bavari Generation of virus-like particles and use as panfilovirus vaccine
EP2497831B1 (en) 2004-05-25 2014-07-16 Oregon Health and Science University TB vaccination using HCMV-based vaccine vectors
ES2539010T3 (es) 2004-08-27 2015-06-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus MVA recombinantes que expresan genes env, gag y pol modificados de VIH clado A/G, clado B, y clado C
EP2526957A3 (en) * 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
ES2281252B1 (es) 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
US20100047277A1 (en) 2006-07-13 2010-02-25 Compans Richard W Virosomes, methods of preparation, and immunogenic compositions
US9133478B2 (en) 2006-08-25 2015-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes
US20090092628A1 (en) 2007-03-02 2009-04-09 James Mullins Conserved-element vaccines and methods for designing conserved-element vaccines
AU2008275513A1 (en) 2007-05-02 2009-01-15 Emory University Enhancement of glycoprotein incorporation into virus-like particles
ES2496916T3 (es) 2007-05-31 2014-09-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Epítopo de HPV al que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas
US11202775B2 (en) 2007-09-25 2021-12-21 Minerva Biotechnologies Corporation Methods for treatment of cancer
WO2009079564A2 (en) 2007-12-17 2009-06-25 Emory University Immunogenic compositions and methods of use thereof
WO2011034953A2 (en) 2009-09-16 2011-03-24 The Administrators Of The Tulane Educational Fund Lassa virus-like particles and methods of production thereof
AP2012006258A0 (en) 2009-10-13 2012-06-30 Geovax Inc Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens.
CN102844663B (zh) * 2010-01-27 2016-01-06 俄勒冈健康科学大学 基于巨细胞病毒的免疫原性制剂
CA2790426A1 (en) 2010-02-18 2011-08-25 Emory University Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response
US20120052082A1 (en) 2010-04-09 2012-03-01 Zetra Biologicals, LLC Cross-protective influenza vaccine
WO2011130627A2 (en) 2010-04-16 2011-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Chimpanzee adenoviral vector-based filovirus vaccines
WO2011156751A2 (en) 2010-06-11 2011-12-15 University Of Georgia Research Foundation, Inc. Immunogenic vaccine
EP2670430B1 (en) * 2011-01-31 2015-04-01 Baxter International Inc Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses
CN103945863A (zh) 2011-08-01 2014-07-23 爱默蕾大学 包含配体的vlp及其相关方法
US20130280215A1 (en) 2011-10-18 2013-10-24 Geovax, Inc. Mva vectors expressing polypeptides and having high level production in certain cell lines
US9463238B2 (en) 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C
JP2015522580A (ja) 2012-07-06 2015-08-06 ノバルティス アーゲー 免疫学的組成物およびその使用
EP2945649B1 (en) 2013-01-22 2018-12-12 Oxford University Innovation Limited Composition and uses thereof
WO2015009946A1 (en) 2013-07-17 2015-01-22 Emory University Method of increasing immune response to hiv antigens
CA3205348A1 (en) 2013-10-23 2015-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
WO2015066715A1 (en) 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Virus-like particles and methods related thereto
AU2015259516B2 (en) * 2014-05-13 2020-05-28 Bavarian Nordic A/S Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3
SG10201901735XA (en) * 2014-09-03 2019-03-28 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
WO2016068919A1 (en) 2014-10-29 2016-05-06 Geovax, Inc. Combination therapy for treating viral reservoirs
EP3244919A4 (en) 2015-01-12 2018-06-27 Geovax, Inc. Compositions and methods for generating an immune response to a hemorrhagic fever virus
US10072058B2 (en) 2015-04-29 2018-09-11 Emory University Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates
PL3402802T3 (pl) 2016-01-08 2023-06-05 Geovax, Inc. Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym
WO2017136419A1 (en) 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
AU2017221379A1 (en) 2016-02-16 2018-08-16 Geovax Inc. Multivalent HIV vaccine boost compositions and methods of use
US11052148B2 (en) 2016-05-30 2021-07-06 Geo Vax, Inc. Compositions and methods for generating an immune response to hepatitis B virus
WO2018195447A1 (en) 2017-04-20 2018-10-25 Geovax Labs, Inc. Recombinant mva-based hiv immunogens and uses thereof
WO2019018501A1 (en) 2017-07-18 2019-01-24 Geovax Inc. COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE
WO2019040846A1 (en) 2017-08-25 2019-02-28 Geovax Inc. IMMUNO-ONCOLOGY COMPOSITIONS AND METHODS OF USE THEREOF
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
WO2020247547A1 (en) 2019-06-03 2020-12-10 Geovax, Inc. Cancer vaccine compositions and methods for use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013014588A (ja) 2005-01-24 2013-01-24 Gsf-Forschungszentrum Fuer Umwelt & Gesundheit Gmbh Ｍｖａの使用に基づくワクチン
US20060286074A1 (en) 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
CN101460627A (zh) 2006-06-20 2009-06-17 特朗斯吉有限公司 制备痘病毒的方法以及痘病毒组合物
JP2009540806A (ja) 2006-06-20 2009-11-26 トランジェーヌ、ソシエテ、アノニム ポックスウイルスおよびポックスウイルス組成物の製造方法
JP2012507985A (ja) 2008-11-03 2012-04-05 リゴサイト ファーマシューティカルズ インコーポレイテッド 感染因子を含まないエンベロープウイルスベースｖｌｐを単離するための改良法
JP2013507935A (ja) 2009-10-16 2013-03-07 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ 再構築された挿入部位を含有する組換え改変ワクシニアアンカラ（ｍｖａ）ワクシニアウイルス

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Fend L. et al.，Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with TLR9 agonist，Cancer Immunology research，2014年，Vol. 2, No, 12，p. 1163-1174

Also Published As

Publication number Publication date
AU2021261945A1 (en) 2021-12-02
US11413341B2 (en) 2022-08-16
EP3402802B1 (en) 2023-04-12
CA3011014A1 (en) 2017-07-13
CN109071592B (zh) 2022-07-19
PL3402802T3 (pl) 2023-06-05
US20190290745A1 (en) 2019-09-26
CN116064669A (zh) 2023-05-05
AU2017206102A1 (en) 2018-07-19
JP2024056839A (ja) 2024-04-23
EP3402802A4 (en) 2019-08-21
US11278607B2 (en) 2022-03-22
ES2944314T3 (es) 2023-06-20
AU2017206102B2 (en) 2021-08-26
CN109071592A (zh) 2018-12-21
US20230040403A1 (en) 2023-02-09
WO2017120577A1 (en) 2017-07-13
EP3402802A1 (en) 2018-11-21
US20200289633A1 (en) 2020-09-17
AU2017206102C1 (en) 2022-02-10
JP2019500907A (ja) 2019-01-17
JP2022185011A (ja) 2022-12-13
AU2021261945B2 (en) 2024-12-12
US12247214B2 (en) 2025-03-11

Similar Documents

Publication Publication Date Title
JP7150611B2 (ja) 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法
US20220160853A1 (en) Cancer vaccine compositions and methods for use thereof
US20230256088A1 (en) Immuno-oncology compositions and methods for use thereof
ES2626261T3 (es) Método de quimioinmunoterapia
EP4450516A2 (en) A vaccine for use in the prophylaxis and/or treatment of a disease
EP3877531A1 (en) Alphavirus neoantigen vectors and interferon inhibitors
KR20200076696A (ko) 백신 t 세포 인핸서
EP3244919A1 (en) Compositions and methods for generating an immune response to a hemorrhagic fever virus
JP2024505274A (ja) ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト
CN109641044A (zh) 用于产生对乙型肝炎病毒的免疫应答的组合物和方法
IL293012A (en) Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva
JP2024534442A (ja) ネオ抗原アジュバント及び維持療法
US11299516B2 (en) DAGRS: directed antigonists to cancer cell growth signals
EP4031253A1 (en) Methods and compositions for treating myc-driven cancers
EP4667485A2 (en) A vaccine for use in the prophylaxis and/or treatment of a disease
CN115135338A (zh) 包含具有二硫桥重排的人vegf-a突变体的多肽以及包含其的组合物
HK40048152A (en) A vaccine for use in the prophylaxis and/or treatment of a disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220412

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220928

R150 Certificate of patent or registration of utility model

Ref document number: 7150611

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250